Department of Anesthesiology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
J Anesth. 2018 Aug;32(4):592-598. doi: 10.1007/s00540-018-2519-3. Epub 2018 Jun 9.
This study aimed to investigate whether dexmedetomidine had sedative weaning advantage for extubation after airway foreign body (FB) removal in children.
A retrospective case-cohort comparison study with total of 57 critical children who required mechanical ventilation after rigid bronchoscopy was performed. After tracheal intubation, group D (received dexmedetomidine 1 µg/kg over 10 min, followed by an infusion of 0.8 µg/kg/h), and group RP (received remifentanil-propofol 6-10 µg/kg/h and 1-3 mg/kg/h, respectively). The primary outcome was successful extubation rate on first weaning trial. The minor outcomes included weaning time, emergency agitation, coughing score and the incidence of respiratory adverse complications on emergency.
All 57 patients were included in the analysis, with 30 patients in group D and 27 controlled cases in group RP. The success rate of first weaning trial in the D group was 96.7 vs 77.8% in the RP group, risk ratio (RR) 1.56, 95% CI [0.78-1.98]. Time for resuming spontaneous breathing after termination infusion was shorter in the D group (median 8 min, IQR 15 min) vs RP group (median 12 min, IQR 19 min, P = 0.02, RR 0.56, 95% CI 0.14-6.57).
In mechanical ventilation of pediatric patients following rigid bronchoscopy, in comparison to remifentanil-propofol, dexmedetomidine is proved to have high success rate for weaning strategy. WHAT IS ALREADY KNOWN?: Remifentanil is proved to be effective for weaning in ICU patients. Dexmedetomedine can provide similar rates of smooth extubation for pediatric patients who underwent airway surgery. WHAT THIS ARTICLE ADDS?: Invasive ventilation is used for patients with severe comorbidity after airway surgery, but the correct strategy for pediatric extubation after removal of airway foreign body remains unclear. For these patients with short-term mechanical ventilation, dexmedetomedine may improve the extubation rate, when compared with remifentanil-propofol.
本研究旨在探讨右美托咪定在小儿气道异物(FB)取出后拔管时是否具有镇静撤药优势。
采用回顾性病例对照研究,共纳入 57 例因硬质支气管镜检查后需要机械通气的危重症儿童。气管插管后,D 组(接受右美托咪定 1μg/kg 静脉推注 10 分钟,然后以 0.8μg/kg/h 的速度输注)和 RP 组(分别接受瑞芬太尼-丙泊酚 6-10μg/kg/h 和 1-3mg/kg/h)。主要结局为首次撤机试验时的拔管成功率。次要结局包括撤机时间、紧急激惹、咳嗽评分以及紧急情况下呼吸不良并发症的发生率。
所有 57 例患者均纳入分析,D 组 30 例,RP 组 27 例对照。D 组首次撤机试验成功率为 96.7%,RP 组为 77.8%,风险比(RR)为 1.56,95%CI[0.78-1.98]。D 组停药后恢复自主呼吸的时间更短(中位数 8 分钟,IQR 15 分钟),而 RP 组(中位数 12 分钟,IQR 19 分钟,P=0.02,RR 0.56,95%CI 0.14-6.57)。
与瑞芬太尼-丙泊酚相比,在硬质支气管镜检查后小儿机械通气中,右美托咪定在撤机策略中被证明具有较高的成功率。
瑞芬太尼已被证明在 ICU 患者中用于撤机有效。右美托咪定可使接受气道手术的小儿患者平稳拔管率相似。
气道手术后严重合并症的患者需要进行有创通气,但气道异物取出后小儿拔管的正确策略仍不清楚。对于这些短期机械通气的患者,与瑞芬太尼-丙泊酚相比,右美托咪定可能提高拔管率。